Aquestive
AQST
Aquestive (AQST) news
Recent news
Aquestive Therapeutics, Inc. Q2 EPS USD -0.18
Aquestive Therapeutics, Inc. (NASDAQ:AQST) reported a second-quarter 2023 earnings per share (EPS) loss of $0.18, reflecting continued financial challenges for the pharmaceutical company. The loss marked a significant decline from the prior year period, where the company recorded a net loss of…
AInvest Wire · Aug 11, 2026Aquestive Therapeutics Inc: full-year 2026 financial guidance remains unchanged
AInvest Wire · Aug 11, 2026Aquestive Therapeutics: confirms that its supply chain currently remains largely unaffected by both implemented & proposed government tariffs
AInvest Wire · Aug 11, 2026Aquestive Therapeutics Inc: on track to begin ex-U.S. filings of Anaphylm in Q4 2026
AInvest Wire · Aug 11, 2026Aquestive Therapeutics - revised instructions reduce incorrect Anaphylm film placement by over 80%
AInvest Wire · Aug 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.